H. Khoury

A. Mehta, A. Kirk, H. Khoury, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tyr-301 Phosphorylation Inhibits Pyruvate Dehydrogenase by Blocking Substrate Binding and Promotes the Warburg Effect*

Jing Chen, Jianxin Xie, Changliang Shan, 2014, The Journal of Biological Chemistry.

A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

A. Marcus, H. Kantarjian, G. Garcia-Manero, 2012, Cancer.

Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.

Taro Hitosugi, Gary LeRoy, Chuan He, 2012, Cancer cell.

Supplemental Information Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V 600 E Tumor Growth

F. Khuri, J. Arbiser, H. Khoury, 2022 .

Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia

R. Collins, J. Dipersio, E. Wirth, 2017, Cancer.

A cluster of mucormycosis infections in hematology patients: challenges in investigation and control of invasive mold infections in high-risk patient populations.

G. Lyon, K. Wannemuehler, S. Magill, 2011, Diagnostic microbiology and infectious disease.

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

C. Flowers, S. Lonial, J. Kaufman, 2015, British journal of haematology.

Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.

M. Baccarani, J. Dipersio, H. Kantarjian, 2014 .

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Andreas Hochhaus, R. Collins, H. Kantarjian, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

M. Deininger, R. Stone, H. Khoury, 2016, Clinical lymphoma, myeloma & leukemia.

Tools to optimize the functionality of a leukemia clinical trial team

H. Khoury, B. El-Rayes, E. Waller, 2013, Leukemia & lymphoma.

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

J. Cortes, R. Paquette, K. Porkka, 2010, Cancer.

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial.

M. Arbushites, M. Perales, H. Khoury, 2020, Blood.

inhibitors resistance or intolerance to imatinib and other tyrosine kinase Bosutinib safety and management of toxicity in leukemia patients with

T. Brümmendorf, H. Kantarjian, R. Ribeiro, 2014 .

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.

M. Baccarani, H. Kantarjian, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2014 .

CLINICAL TRIALS AND OBSERVATIONS Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and / or nilotinib therapy failure Running head : Bosutinib in CP CML after second-generation TKIs

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2005 .

Generic immunosuppressants in hematopoietic cell transplantation.

Ya-Chen Tina Shih, A. Kesselheim, F. Appelbaum, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

SRPK2 Promotes Leukemia Cell Proliferation by Phosphorylating Acinus and Regulating Cyclin A1

S. Yang, K. Ye, S. Dong, 2022 .

Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia

S. Lonial, Zhengjia Chen, H. Khoury, 2012, Cancer.

150: A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration

C. Flowers, S. Lonial, C. Torre, 2007 .

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis

B. Sandmaier, M. Aljurf, M. Tallman, 2017, Cancer.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

B. Sandmaier, M. Aljurf, R. Gale, 2016, Cancer.

Reduced intensity conditioned allograft yields favorable survival for older adults with B‐cell acute lymphoblastic leukemia

B. Sandmaier, H. Khoury, O. Ringdén, 2017, American journal of hematology.

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Tallman, B. Sandmaier, M. Tallman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).

J. Cortes, Jianxiang Wang, H. Khoury, 2010 .

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

H. Kantarjian, J. Cortes, Zhi-xiang Shen, 2008 .

Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link?

H. Khoury, M. Arellano, M. Gaddh, 2015, Cancer.

Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second‐line agents, and beyond

L. Bernal-Mizrachi, H. Khoury, M. Tighiouart, 2011, Cancer.

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.

A. Zander, J. Szer, M. Horowitz, 2008, Blood.

Management of Advanced-Phase Chronic Myeloid Leukemia

H. Khoury, Z. DeFilipp, 2015, Current Hematologic Malignancy Reports.

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.

H. Kohrt, R. Vij, M. Aljurf, 2012, Blood.

Managing chronic myeloid leukemia: a coordinated team care perspective.

H. Khoury, S. Khanwani, M. Arellano, 2012, Clinical lymphoma, myeloma & leukemia.

Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation

J. Cortes, H. Khoury, F. Nicolini, 2008 .

PROGNOSTIC FACTORS FOR OUTCOMES IN ALLOGENEIC TRANSPLANTATION FOR ADVANCED PHASES OF CHRONIC MYELOID LEUKEMIA IN THE IMATINIB ERA: A CIBMTR ANALYSIS

J. Cortes, J. Szer, M. Horowitz, 2011, Bone Marrow Transplantation.

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Cancer.

4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.

M. Baccarani, H. Kantarjian, F. Haluska, 2016 .

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

C. Flowers, S. Lonial, Zhengjia Chen, 2016, Clinical lymphoma, myeloma & leukemia.

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Blood Cancer Journal.

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

M. Baccarani, J. Cortes, H. Khoury, 2015, Leukemia & lymphoma.

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

H. Kantarjian, J. Cortes, P. Jain, 2013, Haematologica.

Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?

J. Dipersio, H. Khoury, A. Cashen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

H. Kantarjian, J. Lipton, H. Khoury, 2009 .

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial.

H. Kantarjian, J. Cortes, H. Khoury, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

M. Arbushites, J. Dipersio, M. Perales, 2020, Blood advances.

Clinical Cancer esearch cer Therapy : Clinical hase I / II Trial Combining High-Dose Melphalan and ologous Transplant with Bortezomib for Multiple Myeloma : R ose-and Schedule-Finding Study

C. Flowers, C. Torre, J. Kaufman, 2010 .

hematopoietic stem cell transplantation Impact of posttransplantation G-CSF on outcomes of allogeneic

R. Gale, H. Khoury, P. McCarthy, 2011 .

Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.

M. Horowitz, R. Gale, P. Tiberghien, 2006, Blood.

Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B‐Cell acute lymphoblastic leukemia

B. Sandmaier, H. Khoury, D. Weisdorf, 2017, Cancer.

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview

H. Khoury, N. Wilson, A. Shen, 2014, Therapeutic advances in hematology.

Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety

R. Stone, H. Khoury, M. Mauro, 2008 .

The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac.

H. Fu, L. Ratner, L. Bernal-Mizrachi, 2012, Leukemia research.

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

B. Sandmaier, M. Horowitz, R. Gale, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Biomarkers of immune activation to screen for severe, acute GVHD

R. Bostick, W. Flanders, H. Khoury, 2011, Bone Marrow Transplantation.

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

J. Dipersio, H. Khoury, D. Roberts, 2018, Bone Marrow Transplantation.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

R. Larson, G. Rosti, J. Cortes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells

C. Flowers, S. Lonial, J. Kaufman, 2013 .

Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies

L. Bernal-Mizrachi, H. Khoury, J. Galipeau, 2013, Cancer.

Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission

B. Sandmaier, M. Horowitz, H. Khoury, 2017, Cancer.

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia

J. Cortes, H. Khoury, A. Shen, 2016, Expert review of hematology.

Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.

Robert A. Egnatchik, R. Deberardinis, N. Seyfried, 2015, Cancer cell.

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

M. Baccarani, H. Kantarjian, J. Cortes, 2013, Haematologica.

Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy

H. Khoury, D. Bixby, 2015, Leukemia & lymphoma.

Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.

B. Garcia, Erwin G. Van Meir, F. Khuri, 2014, Molecular cell.

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.

D. Fabbro, Michael S. Cohen, J. Taunton, 2006, Cancer cell.

Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation

F. Khuri, P. Jin, S. Lonial, 2013, Nature Communications.

p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.

J. Taunton, W. Leonard, Tae-Wook Chung, 2010, Blood.

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

F. Khuri, S. Lonial, O. Abdel-Wahab, 2017, Cell metabolism.

6-phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumor growth by inhibiting LKB1-AMPK signaling

Jing Chen, Taro Hitosugi, Jianxin Xie, 2014, Nature Cell Biology.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

R. Larson, R. Baron, M. Baccarani, 2014, Cancer cell.

A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia

Michael R. Green, L. Zhu, B. Druker, 2014, Science Translational Medicine.

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

J. Dipersio, M. Tallman, R. Gale, 2010, Blood.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

T. Clackson, M. Baccarani, J. Dipersio, 2013, The New England journal of medicine.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2012, Blood.

Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation

J. Taunton, S. Lonial, T. Boggon, 2009, Molecular and Cellular Biology.

Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.

A. Gratwohl, J. Szer, M. Horowitz, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire.

Bruce R. Blazar, Allan D. Kirk, John Horan, 2015, Blood.

Safety and survival outcomes for bloodless transplantation in patients with myeloma

C. Flowers, S. Lonial, J. Kaufman, 2018, Cancer.

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?

M. Pasquini, K. Ballen, H. Khoury, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Kirk A Easley, N. Shenvi, H. Khoury, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: res

C. Flowers, S. Lonial, C. Torre, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors

C. Flowers, S. Lonial, J. Kaufman, 2014, Bone Marrow Transplantation.

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

T. Brümmendorf, G. Martinelli, J. Cortes, 2008, Leukemia.

Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.

C. Flowers, S. Lonial, J. Kaufman, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma

J. Vose, C. Flowers, S. Lonial, 2013, Transfusion.

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

T. Brümmendorf, H. Kantarjian, G. Martinelli, 2011, Blood.

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype

I. Lossos, Y. Natkunam, C. Flowers, 2017, Oncogene.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated

S. Nikiforow, H. Nakasone, J. Pidala, 2018, Haematologica.

Characteristics and outcomes of diffuse large B‐cell lymphoma presenting in leukaemic phase

D. Weisenburger, J. Armitage, M. Bast, 2012, British journal of haematology.

Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

R. Gale, H. Khoury, O. Ringdén, 2009, British journal of haematology.

Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.

J. Cortes, M. Aljurf, J. Szer, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Martin C. Müller, E. Kimby, J. Delabie, 2008, Blood.

Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth*

F. Khuri, D. Shin, T. Boggon, 2014, The Journal of Biological Chemistry.

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

J. Szer, B. George, M. Tallman, 2010, Blood.

Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study

C. Flowers, S. Lonial, A. Nooka, 2017, Infection Control & Hospital Epidemiology.

Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome

Wei Zheng, F. Ravandi, E. Jabbour, 2015, Leukemia & lymphoma.

Improved survival after acute graft-versus-host disease diagnosis in the modern era

Alan M. Miller, R. Vij, W. Wood, 2017, Haematologica.

The role of observational studies in optimizing the clinical management of chronic myeloid leukemia

H. Khoury, M. Mauro, T. Zyczynski, 2015, Therapeutic advances in hematology.

Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters

C. Flowers, H. Khoury, E. Waller, 2010, Leukemia & lymphoma.

Venous access catheter-related thrombosis in patients with cancer

Kei Yamada, H. Khoury, M. Gaddh, 2014, Leukemia & lymphoma.

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.

B. Sandmaier, R. Gale, H. Khoury, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Leukemia & lymphoma.

Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).

M. Baccarani, H. Kantarjian, J. Cortes, 2017 .

A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.

J. Dipersio, J. Wigginton, G. Martinelli, 2017 .

Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma.

J. Vose, J. Winter, P. Hari, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

Mourad Tighiouart, Christopher R Flowers, R Donald Harvey, 2010, Clinical Cancer Research.

H. Khoury, E. Waller, A. Langston, 2014, International journal of radiation oncology, biology, physics.

Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma

L. Bernal-Mizrachi, H. Khoury, E. Waller, 2014, Leukemia & lymphoma.

Copper Deficiency Remains An Underappreciated Cause of Ineffective Hematopoiesis

C. Kempton, H. Khoury, T. Ziegler, 2008 .

Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia

H. Khoury, V. Kota, Brittany G Hill, 2014, Expert review of anticancer therapy.

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia

H. Khoury, F. E. Rassi, F. Rassi, 2013, Pharmacogenomics and personalized medicine.

Clinical significance of quantitative monitoring and mutational analysis of BCR-ABL1 transcript in Philadelphia chromosome positive B lymphoblastic leukemia

H. Khoury, M. Arellano, K. Mann, 2016, Leukemia & lymphoma.

Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with Favorable Outcomes In High-Risk Acute Myeloid Leukemia (AML)

R. Collins, Jennifer A. Smith, J. Dipersio, 2010 .

Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT.

R. Collins, Jennifer A. Smith, J. Dipersio, 2009 .

A randomized clinical trial comparing granulocyte–colony‐stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation

C. Flowers, S. Lonial, J. Kaufman, 2011, Transfusion.

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.

P. Tamayo, S. Fröhling, D. Brat, 2015, Molecular cell.

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers

F. Khuri, S. Lonial, O. Abdel-Wahab, 2017, The Journal of Biological Chemistry.

Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529*

S. Lonial, T. Gu, A. Guo, 2008, Journal of Biological Chemistry.

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

T. Brümmendorf, H. Kantarjian, J. Cortes, 2015, British journal of haematology.

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia.

H. Khoury, Brittany G Hill, F. El Rassi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Zhengjia Chen, H. Khoury, M. Arellano, 2017, Cancer.

Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.

H. Kantarjian, J. Cortes, J. Lipton, 2008 .

Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2014 .

Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.

M. Baccarani, H. Kantarjian, F. Haluska, 2014 .

Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: One-year results of CA180–035

J. Dipersio, H. Kantarjian, H. Khoury, 2007 .

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Martin C. Müller, M. Baccarani, J. Dipersio, 2013 .

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

M. Baccarani, J. Cortes, C. Chuah, 2013 .

Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).

J. Lipton, H. Khoury, D. Rizzieri, 2009 .

Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.

T. Brümmendorf, G. Martinelli, J. Cortes, 2010 .

Safety and Efficacy Study of Subcutaneous Homoharringtonine (SC HHT) in Imatinib (IM)-Resistant Chronic Myeloid Leukemia (CML) with the T315I Mutation - Initial Report of a Phase II Trial.

H. Kantarjian, J. Cortes, H. Khoury, 2007 .

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

H. Khoury, M. Arellano, E. Winton, 2015 .

Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM).

T. Brümmendorf, H. Kantarjian, J. Cortes, 2010 .

A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD

A. Mehta, H. Khoury, M. Qayed, 2012 .

Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation

H. Khoury, M. Arellano, A. Langston, 2017, Hematology Reports.

Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to anti-malarial agent dihydroartemisinin

F. Khuri, S. Lonial, T. Boggon, 2016, Oncogene.

Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).

J. Cortes, R. Paquette, H. Khoury, 2014 .

To G or not to G: is this still a question in allogeneic transplantation?

H. Khoury, N. Hawk, 2009, Bone Marrow Transplantation.

Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017.

H. Khoury, R. Hehlmann, L. Williams, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017.

H. Khoury, R. Hehlmann, L. Williams, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Martin C. Müller, M. Baccarani, H. Kantarjian, 2015 .

PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.

Martin C. Müller, M. Baccarani, J. Dipersio, 2012 .

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

J. Dipersio, H. Kantarjian, J. Cortes, 2018, Blood Cancer Journal.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2012, Blood.

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib

E. Vellenga, H. Kantarjian, J. Cortes, 2012 .